CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade EyePoint Pharmaceuticals, Inc. - EYPT CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

EyePoint Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 2.19-15.63
Average Volume (10 days) 601.24K
Average Volume (3 months) 12.31M
Market Cap 351.94M
P/E Ratio -100.00K
Shares Outstanding 34.98M
Revenue 37.33M
EPS -2.83
Dividend (Yield %) N/A
Beta 1.35
Next Earnings Date Oct 31, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low

EyePoint Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Tuesday, September 26, 2023

Time (UTC)

17:15

Country

US

Event

EyePoint Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference
EyePoint Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Forecast

-

Previous

-
Tuesday, October 10, 2023

Time (UTC)

17:45

Country

US

Event

EyePoint Pharmaceuticals Inc at JonesTrading Healthcare Summit
EyePoint Pharmaceuticals Inc at JonesTrading Healthcare Summit

Forecast

-

Previous

-
Tuesday, October 31, 2023

Time (UTC)

12:30

Country

US

Event

Q3 2023 EyePoint Pharmaceuticals Inc Earnings Release
Q3 2023 EyePoint Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Thursday, February 29, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 EyePoint Pharmaceuticals Inc Earnings Release
Q4 2023 EyePoint Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 41.404 36.939 34.437 20.365 2.928
Revenue 41.404 36.939 34.437 20.365 2.928
Total Operating Expense 142.6 90.15 72.632 72.036 27.487
Selling/General/Admin. Expenses, Total 60.324 53.078 45.429 47.711 17.075
Research & Development 49.642 28.5 17.424 15.368 10.412
Unusual Expense (Income) 22.258 -2.065 1.495 3.81
Operating Income -101.196 -53.211 -38.195 -51.671 -24.559
Interest Income (Expense), Net Non-Operating -1.058 -5.206 -7.199 -5.122 -20.161
Net Income Before Taxes -102.254 -58.417 -45.394 -56.793 -44.72
Net Income After Taxes -102.254 -58.417 -45.394 -56.793 -44.72
Net Income Before Extra. Items -102.254 -58.417 -45.394 -56.793 -44.72
Net Income -102.254 -58.417 -45.394 -56.793 -44.72
Income Available to Common Excl. Extra. Items -102.254 -58.417 -45.394 -56.793 -44.72
Income Available to Common Incl. Extra. Items -102.254 -58.417 -45.394 -56.793 -44.72
Diluted Net Income -102.254 -58.417 -45.394 -56.793 -44.72
Diluted Weighted Average Shares 37.317 28.758 12.836 10.4307 8.5057
Diluted EPS Excluding Extraordinary Items -2.74015 -2.03133 -3.53646 -5.44479 -5.25765
Diluted Normalized EPS -2.14369 -2.10314 -3.37403 -5.07952 -5.25765
Total Extraordinary Items
Dividends per Share - Common Stock Primary Issue 0
Cost of Revenue, Total 8.326 8.177 5.824 2.687
Gross Profit 33.078 28.762 28.613 17.678
Depreciation / Amortization 2.05 2.46 2.46 2.46
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 9.105 7.683 10.533 10.012 11.565
Revenue 9.105 7.683 10.533 10.012 11.565
Cost of Revenue, Total 1.792 0.64 3.41 1.405 1.734
Gross Profit 7.313 7.043 7.123 8.607 9.831
Total Operating Expense 33.213 29.237 54.268 28.41 30.781
Selling/General/Admin. Expenses, Total 14.635 15.27 14.411 15.228 15.44
Research & Development 15.439 13.327 15.543 11.162 12.992
Depreciation / Amortization 0 0 0.205 0.615 0.615
Operating Income -24.108 -21.554 -43.735 -18.398 -19.216
Interest Income (Expense), Net Non-Operating 1.188 0.39 0.283 -0.022 -0.19
Net Income Before Taxes -22.92 -21.164 -43.452 -18.42 -19.406
Net Income After Taxes -22.92 -21.164 -43.452 -18.42 -19.406
Net Income Before Extra. Items -22.92 -21.164 -43.452 -18.42 -19.406
Net Income -22.92 -21.164 -43.452 -18.42 -19.406
Income Available to Common Excl. Extra. Items -22.92 -21.164 -43.452 -18.42 -19.406
Income Available to Common Incl. Extra. Items -22.92 -21.164 -43.452 -18.42 -19.406
Diluted Net Income -22.92 -21.164 -43.452 -18.42 -19.406
Diluted Weighted Average Shares 37.576 37.486 37.353 37.338 37.322
Diluted EPS Excluding Extraordinary Items -0.60996 -0.56458 -1.16328 -0.49333 -0.51996
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.57412 -0.56458 -0.60913 -0.49333 -0.51996
Unusual Expense (Income) 1.347 0 20.699 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 172.808 237.745 63.118 41.717 47.601
Cash and Short Term Investments 144.561 211.558 44.909 22.214 45.261
Cash & Equivalents 95.633 178.593 44.909 22.214 45.261
Short Term Investments 48.928 32.965
Total Receivables, Net 15.503 18.354 9.453 11.368 0.627
Accounts Receivable - Trade, Net 15.503 18.354 9.453 11.368 0.627
Prepaid Expenses 9.858 4.217 3.419 5.997 1.434
Total Assets 180.356 263.372 91.717 72.971 78.168
Property/Plant/Equipment, Total - Net 7.398 2.728 3.24 3.435 0.288
Property/Plant/Equipment, Total - Gross 9.505 3.984 4.268 4.274 0.983
Accumulated Depreciation, Total -2.107 -1.256 -1.028 -0.839 -0.695
Intangibles, Net 0 22.749 25.209 27.669 30.129
Other Long Term Assets, Total 0.15 0.15 0.15 0.15 0.15
Total Current Liabilities 34.537 23.658 14.888 11.52 21.459
Accounts Payable 5.919 7.385 4.811 4.192 2.64
Accrued Expenses 16.902 15.067 9.013 7.313 18.789
Notes Payable/Short Term Debt 10.475 0 0 0 0
Other Current Liabilities, Total 1.205 1.069 0.945 0.015 0.03
Total Liabilities 83.988 78.992 73.176 64.641 40.535
Total Long Term Debt 29.31 36.598 38.048 47.223 17.621
Other Liabilities, Total 20.141 18.736 20.24 5.898 1.455
Total Equity 96.368 184.38 18.541 8.33 37.633
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.034 0.034 0.018 0.109 0.095
Additional Paid-In Capital 766.899 752.602 528.362 472.667 445.192
Retained Earnings (Accumulated Deficit) -671.351 -569.097 -510.68 -465.286 -408.493
Other Equity, Total 0.786 0.841 0.841 0.84 0.839
Total Liabilities & Shareholders’ Equity 180.356 263.372 91.717 72.971 78.168
Total Common Shares Outstanding 34.0829 33.9058 18.14 10.9417 9.53722
Long Term Debt 29.31 36.562 37.977 47.223 17.621
Total Inventory 2.886 3.616 5.337 2.138 0.279
Current Port. of LT Debt/Capital Leases 0.036 0.137 0.119
Capital Lease Obligations 0 0.036 0.071
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 146.057 172.808 192.102 205.866 219.629
Cash and Short Term Investments 122.483 144.561 157.259 171.167 190.784
Cash & Equivalents 105.765 95.633 75.362 82.134 101.545
Total Receivables, Net 10.422 15.503 20.876 22.594 19.589
Accounts Receivable - Trade, Net 10.422 15.503 20.876 22.594 19.589
Total Inventory 4.071 2.886 3.531 3.254 3.336
Prepaid Expenses 9.081 9.858 10.436 8.851 5.92
Total Assets 154.593 180.356 220.49 233.433 244.555
Property/Plant/Equipment, Total - Net 8.386 7.398 7.334 5.898 2.642
Property/Plant/Equipment, Total - Gross 9.505 6.589 5.057 2.367
Accumulated Depreciation, Total -2.107 -0.206 -0.172 -0.138
Intangibles, Net 0 20.904 21.519 22.134
Other Long Term Assets, Total 0.15 0.15 0.15 0.15 0.15
Total Current Liabilities 27.242 34.537 34.256 33.39 31.971
Accounts Payable 9.453 5.919 6.112 7.058 7.302
Accrued Expenses 11.239 16.902 16.429 14.613 12.97
Notes Payable/Short Term Debt 5.295 10.475 10.475 10.475 10.475
Current Port. of LT Debt/Capital Leases 0.036 0.07 0.105 0.122
Other Current Liabilities, Total 1.255 1.205 1.17 1.139 1.102
Total Liabilities 76.203 83.988 84.14 82.067 77.736
Total Long Term Debt 29.37 29.31 29.251 29.181 29.126
Long Term Debt 29.37 29.31 29.251 29.181 29.108
Capital Lease Obligations 0 0 0 0.018
Other Liabilities, Total 19.591 20.141 20.633 19.496 16.639
Total Equity 78.39 96.368 136.35 151.366 166.819
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.034 0.034 0.034 0.034 0.034
Additional Paid-In Capital 770.028 766.899 763.562 760.209 756.07
Retained Earnings (Accumulated Deficit) -692.515 -671.351 -627.899 -609.479 -590.073
Other Equity, Total 0.843 0.786 0.653 0.602 0.788
Total Liabilities & Shareholders’ Equity 154.593 180.356 220.49 233.433 244.555
Total Common Shares Outstanding 34.3019 34.0829 34.0722 34.0526 34.0471
Short Term Investments 16.718 48.928 81.897 89.033 89.239
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -102.254 -58.417 -45.394 -56.793 -44.72
Cash From Operating Activities -65.005 -50.097 -14.435 -56.699 -22.586
Cash From Operating Activities 0.396 0.311 0.189 0.144 0.097
Amortization 2.05 2.46 2.46 2.46 1.229
Non-Cash Items 37.826 7.288 8.174 10.026 21.748
Cash Taxes Paid
Changes in Working Capital -3.023 -1.739 20.136 -12.536 -0.94
Cash From Investing Activities -17.265 -33.121 -0.362 -0.213 -0.132
Capital Expenditures -2.15 -0.156 -0.362 -0.213 -0.132
Other Investing Cash Flow Items, Total -15.115 -32.965 0 0
Cash From Financing Activities -0.69 216.902 37.492 33.864 29.204
Issuance (Retirement) of Stock, Net 0.395 217.198 50.212 23.041 29.399
Foreign Exchange Effects 0 0.001 -0.001
Net Change in Cash -82.96 133.684 22.695 -23.047 6.485
Cash Interest Paid 2.6 4.846 5.51 4.87 1.241
Financing Cash Flow Items -3.188 -0.15 -0.918 -19.177 -0.195
Issuance (Retirement) of Debt, Net 2.103 -0.146 -11.802 30 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -21.164 -102.254 -58.802 -40.382 -20.976
Cash From Operating Activities -16.835 -65.005 -52.417 -39.281 -20.158
Cash From Operating Activities 0.105 0.396 0.266 0.17 0.081
Amortization 0 2.05 1.845 1.23 0.615
Non-Cash Items 2.806 37.826 12.157 9.172 5.146
Cash Interest Paid 0.74 2.6 1.907 1.349 0.941
Changes in Working Capital 1.418 -3.023 -7.883 -9.471 -5.024
Cash From Investing Activities 32.086 -17.265 -50.182 -56.454 -56.442
Capital Expenditures -0.484 -2.15 -1.565 -0.367 -0.149
Cash From Financing Activities -5.119 -0.69 -0.632 -0.724 -0.448
Financing Cash Flow Items -0.169 -3.188 -3.164 -3.138 -2.896
Issuance (Retirement) of Stock, Net 0.248 0.395 0.395 0.241 0.241
Issuance (Retirement) of Debt, Net -5.198 2.103 2.137 2.173 2.207
Net Change in Cash 10.132 -82.96 -103.231 -96.459 -77.048
Other Investing Cash Flow Items, Total 32.57 -15.115 -48.617 -56.087 -56.293
Foreign Exchange Effects

EyePoint Pharmaceuticals, Inc. Company profile

About Eyepoint Pharmaceuticals Inc

EyePoint Pharmaceuticals, Inc. is a pharmaceutical company that is focused on developing and commercializing therapeutics to help improve eye disorders. The Company's products include EYP-1901, YUTIQ50, DEXYCU and YUTIQ. EYP-1901, which combines a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib, a tyrosine kinase inhibitor. EYP-1901 is in Phase I clinical trial and targeting treatment of wet age-related macular degeneration for additional indications in diabetic retinopathy and retinal vein occlusion. DEXYCU is a single-dose treatment for postoperative inflammation following ocular surgery. YUTIQ50 is a potential twice-yearly treatment for non-infectious uveitis affecting the posterior segment of the eye. YUTIQ is a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. It is utilizing its core technology platform, Durasert to deliver drugs and biologics to treat chronic diseases.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Eyepoint Pharmaceuticals Inc revenues increased 7% to $36.9M. Net loss increased 29% to $58.4M. Revenues reflect DEXYCU segment increase from $7M to $18.4M, YUTIQ segment increase of 22% to $17M, United States segment increase of 59% to $36M. Higher net loss reflects Research and Development Expense increase of 64% to $26.2M (expense), General and administrative increase of 19% to $20.7M (expense).

Equity composition

Common Stock $0.001 Par, 02/11, 60M auth., 20,741,392 issd. Insiders own 11.62%. 8/04 :49,804,381 shs issd @ $1.09each to pSiMedica Ltd on acquisition. 06/08, Name changed from pSivida Limited. 06/08, 1-for-40 reverse stock split.

Industry: Pharmaceuticals (NEC)

480 Pleasant St Ste B300
WATERTOWN
MASSACHUSETTS 02472-2468
US

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

XRP/USD

0.52 Price
+0.330% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

US100

14,787.50 Price
+0.760% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

26,630.10 Price
+0.030% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

ETH/USD

1,597.79 Price
+0.530% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading